Steve Cohen and SAC Capital’s Top Stock Investments in Healthcare

The Dow Jones Industrial Average is pushing higher over 200 points to 11,341 and the S&P 500 is up over 2% to 1,190 today, as Wall St. Watchdog reveals information about SAC Capital’s top holdings in the Healthcare (NYSE:XLV) sector:

  • Dendreon Corp. (NASDAQ:DNDN): On 3/31/11 SAC Capital reported holding 8,203,470 shares with a market value of $307,055,885. This comprised 2.34% of the total portfolio. On 6/30/11, SAC Capital held 8,602,197 shares with a market value of $339,270,638. This comprised 2.46% of the total portfolio. The net change in shares for this position over the two quarters is 398,727. About the company: Dendreon Corporation discovers and develops immunologically based therapeutic products for the treatment of cancer. The Company combines knowledge in immunology and antigen engineering with proprietary cell separation technologies to develop therapeutic vaccines that induce cell-mediated immunity, the body’s key defense against cancer.
  • Express Scripts, Inc. (NASDAQ:ESRX): On 3/31/11 SAC Capital reported holding 3,186,872 shares with a market value of $177,221,954. This comprised 1.35% of the total portfolio. On 6/30/11, SAC Capital held 2,699,566 shares with a market value of $145,722,571. This comprised 1.05% of the total portfolio. The net change in shares for this position over the two quarters is -487,306. About the company: Express Scripts, Inc is a full service pharmacy benefit management and specialty managed care company serving clients throughout North America. The Company’s customers include managed care organizations, insurance carriers, third party administrators, employers, and union-sponsored benefit plans. Express provides pharmacy network management, formulary management, and other services.
  • United Therapeutics Corp. (NASDAQ:UTHR): On 3/31/11 SAC Capital reported holding 494,239 shares with a market value of $33,123,896. This comprised 0.25% of the total portfolio. On 6/30/11, SAC Capital held 2,184,233 shares with a market value of $120,351,235. This comprised 0.87% of the total portfolio. The net change in shares for this position over the two quarters is 1,689,994. About the company: United Therapeutics Corporation develops pharmaceuticals to treat vascular diseases such as pulmonary hypertension and peripheral vascular disease. The Company’s lead products are stable synthetic forms of prostacyclin and are delivered orally or subcutaneously. United’s products are currently in Phase III clinical trials.
  • Community Health Systems, Inc. (NYSE:CYH): On 3/31/11 SAC Capital reported holding 793,917 shares with a market value of $31,748,742. This comprised 0.24% of the total portfolio. On 6/30/11, SAC Capital held 4,097,046 shares with a market value of $105,212,143. This comprised 0.76% of the total portfolio. The net change in shares for this position over the two quarters is 3,303,129. About the company: Community Health Systems Inc. owns, leases, and operates hospitals in multiple states. The Hospitals services include emergency room services, general surgery, critical care, internal medicine, obstetrics and diagnostic services. Community Health also owns interests in physicians, physician practices, imaging centers, home health agencies and ambulatory surgery centers.
  • Covidien PLC (NYSE:COV): On 3/31/11 SAC Capital reported holding 1,211,407 shares with a market value of $62,920,478. This comprised 0.48% of the total portfolio. On 6/30/11, SAC Capital held 1,918,095 shares with a market value of $102,100,196. This comprised 0.74% of the total portfolio. The net change in shares for this position over the two quarters is 706,688. About the company: Covidien PLC is a global healthcare products company. The Company develops, manufactures and distributes a diverse range of medical devices and supplies, diagnostics imaging agents, pharmaceuticals and other healthcare products for use in clinical and home settings.
  • Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN): On 3/31/11 SAC Capital reported holding 4,604,779 shares with a market value of $52,356,337. This comprised 0.40% of the total portfolio. On 6/30/11, SAC Capital held 7,083,953 shares with a market value of $94,641,610. This comprised 0.68% of the total portfolio. The net change in shares for this position over the two quarters is 2,479,174. About the company: Amylin Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, develops, and commercializes medicines for diabetes and obesity. The Company’s marketed products include treatments for adults with type 1 and type 2 diabetes.
  • McKesson Corporation (NYSE:MCK): On 3/31/11 SAC Capital reported holding 1,063,453 shares with a market value of $84,065,963. This comprised 0.64% of the total portfolio. On 6/30/11, SAC Capital held 1,048,003 shares with a market value of $87,665,453. This comprised 0.63% of the total portfolio. The net change in shares for this position over the two quarters is -15,450. About the company: McKesson Corporation distributes pharmaceuticals, medical-surgical supplies, and and health and beauty care products throughout North America. The Company also develops, implements, and supports software that facilitates the integration of data throughout the health enterprise. In addition, McKesson offers analytic, care management, and patient solutions for payers.
  • Stryker Corp. (NYSE:SYK): On 3/31/11 SAC Capital reported holding 70,573 shares with a market value of $4,290,838. This comprised 0.03% of the total portfolio. On 6/30/11, SAC Capital held 1,381,809 shares with a market value of $81,098,368. This comprised 0.59% of the total portfolio. The net change in shares for this position over the two quarters is 1,311,236. About the company: Stryker Corporation develops, manufactures, and markets specialty surgical and medical products. The Company’s products include implants, biologics; surgical, neurologic, ear, nose & throat and interventional pain equipment; endoscopic, surgical navigation, communications and digital imaging systems; as well as patient handling and emergency medical equipment.
  • Acorda Therapeutics, Inc. (NASDAQ:ACOR): On 3/31/11 SAC Capital reported holding 1,816,524 shares with a market value of $42,143,358. This comprised 0.32% of the total portfolio. On 6/30/11, SAC Capital held 2,361,677 shares with a market value of $76,305,787. This comprised 0.55% of the total portfolio. The net change in shares for this position over the two quarters is 545,153. About the company: Acorda Therapeutics Inc. is a biotechnology company that is developing therapies for spinal cord injury and related neurological conditions, including multiple sclerosis. Additionally, Acorda is developing multiple approaches to regeneration and repair of the spinal cord and brain.
  • Thermo Fisher Scientific, Inc. (NYSE:TMO): On 3/31/11 SAC Capital reported holding 497,002 shares with a market value of $27,608,461. This comprised 0.21% of the total portfolio. On 6/30/11, SAC Capital held 1,082,932 shares with a market value of $69,729,991. This comprised 0.50% of the total portfolio. The net change in shares for this position over the two quarters is 585,930. About the company: Thermo Fisher Scientific, Inc. manufactures scientific instruments, consumables, and chemicals. The Company offers analytical instruments, laboratory equipment, software, services, consumables, reagents, chemicals, and supplies to pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions, and government agencies.

(Note: Data on SAC Capital’s holdings are sourced from whalewisdom.com.  All data are assumed to be accurate.)

Advantage: Check out our interactive stock charts, fundamentals, Twitter stream, and more >>

Popular: Is China Buying Gold to Challenge the U.S. Dollar?>>